Patients and Methods.
The study was carried out in Spain, between April 1, 2019 and January 31, 2020, coordinated by the working group on osteoporosis and mineral metabolism of the Spanish Society of Internal Medicine (SEMI). Patients who had previously received a minimum of one year of DMAB treatment, injecting at least 2 doses, having produced a minimum delay of 2 months from the moment of injection, were included. Patients must have suffered at least one fragility fracture after discontinuation of DMAB. This fracture was verified by a lateral radiography of the thoracic and lumbar spine, an MRI of the entire spine, or both. Genant’s classification (12) was applied to diagnose vertebral fracture. Those patients with cancer, Paget’s disease of bone or when the fracture was traumatic were excluded. The collection of clinical data was carried out with a questionnaire designed for this purpose.